Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CCR9 | P51686 | 15/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035744 | 0.90 | CCR9 (0.47) | CCR9PIK3CDHSD17B2 | |
| SCHEMBL1037648 | 0.85 | HSD17B2 (0.50) | CCR9PIK3CDHSD17B2 | |
| SCHEMBL1035802 | 0.82 | CCR9 (0.44) | CCR9PIK3CDHSD17B2 | |
| SCHEMBL1038886 | 0.81 | HSD17B2 (0.47) | CCR9PIK3CDHSD17B2 | |
| SCHEMBL1033742 | 0.79 | CCR9 (0.50) | CCR9PIK3CDHSD17B2 | |
| SCHEMBL4035988 | 0.79 | CCR9 (0.47) | CCR9PIK3CDHSD17B2 | |
| SCHEMBL1036879 | 0.78 | HSD17B2 (0.49) | CCR9PIK3CDHSD17B2 | |
| SCHEMBL1035106 | 0.77 | HSD17B2 (0.47) | CCR9PIK3CDHSD17B2 | |
| SCHEMBL1036935 | 0.77 | CCR9 (0.48) | CCR9HSD17B2 | |
| SCHEMBL1035038 | 0.77 | HSD17B2 (0.44) | CCR9PIK3CDHSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049515-B1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES AS CCR2 OR CCR9 MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS | CHEMOCENTRYX INC (US) | 2011-01-26 | — | — | EP | claimed |
| US-20100152186-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | claimed |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | claimed |
| US-8445518-B2 | Triazolyl pyridyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445518-B2 | Triazolyl pyridyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445518-B2 | Triazolyl pyridyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2049515-B1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES AS CCR2 OR CCR9 MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS | CHEMOCENTRYX INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100152186-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152186-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152186-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7683176-B2 | Triazolyl pyridyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683176-B2 | Triazolyl pyridyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683176-B2 | Triazolyl pyridyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| EP-2049515-A2 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES AS CCR2 OR CCR9 MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS | ChemoCentryx Inc (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| WO-2008008375-A2 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES AS CCR2 OR CCR9 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008375-A2 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES AS CCR2 OR CCR9 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | ALDH1A1 2696/4885POLB 3703/4885HTT 3160/4885 |
| US-20100152186-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | ALDH1A1 2696/4885POLB 3703/4885HTT 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.